ライフサイエンスコーパス: Acinetobacter baumannii

1 and the full-length acetyltransferase WeeI (Acinetobacter baumannii).

2 erobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii).

3 designed an assay for the emerging pathogen Acinetobacter baumannii.

4 ella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii.

5 ns caused by Gram-negative pathogens such as Acinetobacter baumannii.

6 consensus method for the active screening of Acinetobacter baumannii.

7 ed protein (Bap) in a bloodstream isolate of Acinetobacter baumannii.

8 ctivity do not address MDR pathogens such as Acinetobacter baumannii.

9 (ESBL)-producing Enterobacteriaceae and MDR Acinetobacter baumannii.

10 t defense against the opportunistic pathogen Acinetobacter baumannii.

11 istant strains of Pseudomonas aeruginosa and Acinetobacter baumannii.

12 ncy against the opportunistic human pathogen Acinetobacter baumannii.

13 lecular Microbiology, structural analysis in Acinetobacter baumannii 17978 revealed that a pentasacch

14 of the isolates from the Iraqi conflict were Acinetobacter baumannii (189 of 216 isolates).

15 The Acinetobacter baumannii 19606 prototype strain produces

16 Twenty-eight infectious episodes due to Acinetobacter baumannii (46.4%), Klebsiella pneumoniae (

17 siella pneumoniae [10], carbapenem-resistant Acinetobacter baumannii [8], carbapenem- and quinolone-r

18 Acinetobacter baumannii A118 was isolated from a patient

19 ial pathogens Acinetobacter nosocomialis and Acinetobacter baumannii ("aCif").

20 sted against the class C cephalosporinase of Acinetobacter baumannii [Acinetobacter-derived cephalosp

21 Acinetobacter baumannii, Acinetobacter nosocomialis, and

22 options exist for extensively drug resistant Acinetobacter baumannii, an emerging threat in ICUs worl

23 l monomicrobial necrotizing fasciitis due to Acinetobacter baumannii, an unusual finding that may be

24 Pathogenic Acinetobacter species, including Acinetobacter baumannii and Acinetobacter nosocomialis,

25 Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae are al

26 clinically relevant Gram-negative pathogens, Acinetobacter baumannii and Klebsiella pneumoniae.

27 in combination against Enterococcus faecium, Acinetobacter baumannii and Klebsiella pneumoniae.

28 gues when used alone lacked activity against Acinetobacter baumannii and Klebsiella pneumoniae; howev

29 ilar protocols have been proposed to include Acinetobacter baumannii and Pseudomonas aeruginosa (SNAP

30 ymyxin resistant recent clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa .

31 ority bacteria included carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, and

32 ent combination against clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa.

33 e-scaffolds would be more effective against Acinetobacter baumannii and Staphylococcus aureus biofil

34 antibacterial leads against 119 targets from Acinetobacter baumannii and Staphylococcus aureus.

35 erial growth after 24h for Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus.

36 tive (Staphylococcus aureus), Gram-negative (Acinetobacter baumannii), and fungal (Candida albicans)

37 tive (Staphylococcus aureus), gram-negative (Acinetobacter baumannii), and fungal (Candida albicans)

38 lococcus epidermidis, Enterococcus faecalis, Acinetobacter baumannii, and Candida albicans Catheters

39 Klebsiella pneumonia, Enterobacter cloacae, Acinetobacter baumannii, and methicillin-resistant Staph

40 d 100 well-characterized Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa isol

41 ococcus spp., members of the orange complex, Acinetobacter baumannii, and Pseudomonas aeruginosa were

42 ematic in hospitals: Pseudomonas aeruginosa, Acinetobacter baumannii, and Staphylococcus aureus.

43 cally troublesome pathogens, the prokaryote, Acinetobacter baumannii, and the eukaryote, Candida albi

44 Infections caused by the bacterial pathogen Acinetobacter baumannii are a mounting concern for healt

45 essential genes in Acinetobacter lwoffii and Acinetobacter baumannii are active in vitro and in vivo.

46 esistant forms of the Gram-negative pathogen Acinetobacter baumannii are an emerging threat to human

47 s for infections due to carbapenem-resistant Acinetobacter baumannii are extremely limited.

48 Outbreak strains of Acinetobacter baumannii are highly clonal, and cross-inf

49 -negative bacilli Pseudomonas aeruginosa and Acinetobacter baumannii are increasingly acquiring carba

50 Using Acinetobacter baumannii as the model, we then demonstrat

51 yed for the treatment of multidrug-resistant Acinetobacter baumannii, as it can rapidly develop resis

52 ein 33 (Omp33) is an outer membrane porin of Acinetobacter baumannii associated with carbapenem resis

53 plified samples were Prevotella tannerae and Acinetobacter baumannii at frequencies between 89 and 10

54 activity against the Gram-negative pathogen Acinetobacter baumannii ATCC 17961 (MIC = 0.0078 muM).

55 The efficacy of antimicrobial therapy for Acinetobacter baumannii bacteremia has been difficult to

56 Of particular concern are Acinetobacter baumannii bacteria, which recently emerged

57 al targets in 51% of all wound samples, with Acinetobacter baumannii being the most frequently detect

58 ut in vitro screen to identify inhibitors of Acinetobacter baumannii biofilms using a library of natu

59 thogens that express a T2S system(s) include Acinetobacter baumannii, Burkholderia pseudomallei, Chla

60 smic domains from Pseudomonas aeruginosa and Acinetobacter baumannii by BOCILLIN FL, aztreonam, merop

61 the susceptibilities of 107 isolates of the Acinetobacter baumannii-calcoaceticus complex to amikaci

62 standing of aminoglycoside resistance in the Acinetobacter baumannii-calcoaceticus complex.

63 infected or not with Staphylococcus aureus, Acinetobacter baumannii, Candida albicans, or Aspergillu

64 aphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii, carbapenem-resistant Enterobact

65 Acinetobacter baumannii causes severe infections in comp

66 Adhesion is an initial and important step in Acinetobacter baumannii causing infections.

67 cteriaceae spp., Pseudomonas aeruginosa, and Acinetobacter baumannii chosen to provide extreme diagno

68 cient killing by GA was also demonstrated in Acinetobacter baumannii clinical isolates and approximat

69 Genotypes of carbapenem-resistant Acinetobacter baumannii collected by the clinical microb

70 e elements form pathogenicity islands in the Acinetobacter baumannii comM gene.

71 Acinetobacter baumannii complex bacteremia has been iden

72 s, from whom the Acinetobacter calcoaceticus-Acinetobacter baumannii complex was isolated over a 14-m

73 ically important Acinetobacter calcoaceticus-Acinetobacter baumannii complex were found to be more re

74 ydroxyphenylacetate (HPA) 3-hydroxylase from Acinetobacter baumannii consists of a reductase componen

75 We found that Acinetobacter baumannii contains a pgaABCD locus that en

76 Multidrug-resistant Acinetobacter baumannii contamination occurred most freq

77 ruginosa (CP-PA) and carbapenemase-producing Acinetobacter baumannii (CP-AB) and perform a multicente

78 anisms of resistance of carbapenem-resistant Acinetobacter baumannii (CRAB) were determined in hospit

79 Acinetobacter baumannii cultures were multidrug resistan

80 ecium, and silver/copper combination against Acinetobacter baumannii demonstrated antimicrobial syner

81 with MenC or another Gram-negative bacteria, Acinetobacter baumannii, did not inhibit augmented PS-sp

82 jor protein species in the outer membrane of Acinetobacter baumannii does not belong to the high-perm

83 factors associated with transmission risk of Acinetobacter baumannii during patient care.

84 The epidemiology of Acinetobacter baumannii emerging in combat casualties is

85 es its properties to those published for the Acinetobacter baumannii enzyme, an example of the altern

86 igm of clinical infectious disease research, Acinetobacter baumannii, Escherichia coli, Klebsiella pn

87 Other targeted pathogens (Acinetobacter baumannii, extended-spectrum beta-lactamas

88 Acinetobacter baumannii frequently causes nosocomial inf

89 s with molecular methods used to distinguish Acinetobacter baumannii from other members of the A. cal

90 We performed WGS on longitudinal isolates of Acinetobacter baumannii from patients undergoing colisti

91 ideal sampling method for identification of Acinetobacter baumannii from the health care environment

92 comparative analysis on currently completed Acinetobacter baumannii genomes revealed extensive and d

93 the in-hospital mortality was higher in the Acinetobacter baumannii group (16% vs. 13%; odds ratio,

94 cute liver failure were more frequent in the Acinetobacter baumannii group compared to the control gr

95 Acinetobacter baumannii has become an important concern

96 Acinetobacter baumannii has emerged as a highly troubles

97 Although Acinetobacter baumannii has emerged as a significant cau

98 Acinetobacter baumannii has emerged as an important and

99 t emergence of multidrug resistance (MDR) in Acinetobacter baumannii has raised concern in health car

100 Acinetobacter baumannii has recently emerged as a highly

101 rk done over the past 5 years has shown that Acinetobacter baumannii has the remarkable capability to

102 multidrug-resistant, opportunistic pathogen, Acinetobacter baumannii, has spread swiftly through hosp

103 MICs of tigecycline to Acinetobacter baumannii have been reported to be elevate

104 of both drug-susceptible and drug-resistant Acinetobacter baumannii in a soft-tissue infection model

105 fect of the presence of carbapenem-resistant Acinetobacter baumannii in accordance with surveillance

106 domonas aeruginosa, and carbapenem-resistant Acinetobacter baumannii in the pediatric population.

107 re unit length of stay, and complications of Acinetobacter baumannii including multidrug-resistant st

108 e or clinical indifference, the impact of an Acinetobacter baumannii infection on mortality is inconc

109 Acinetobacter baumannii infection was, however, associat

110 intensive care unit patients with confirmed Acinetobacter baumannii infection were defined as cases.

111 In this single-center experience, Acinetobacter baumannii infection, including multidrug-r

112 s for treatment of multidrug-resistant (MDR) Acinetobacter baumannii infections are extremely limited

113 Severe Acinetobacter baumannii infections in immunocompetent pa

114 ulfonate (CMS) to treat carbapenem-resistant Acinetobacter baumannii infections, colistin resistance

115 s Diseases (NSRB) against BasE, an AAAE from Acinetobacter baumannii involved in production of the si

116 Acinetobacter baumannii is a bacterial pathogen of incre

117 Acinetobacter baumannii is a bacterial pathogen of incre

118 Acinetobacter baumannii is a bacterial pathogen with inc

119 Acinetobacter baumannii is a common cause of health care

120 Acinetobacter baumannii is a common nosocomial pathogen

121 The nosocomial pathogen Acinetobacter baumannii is a frequent cause of hospital-

122 Acinetobacter baumannii is a globally distributed nosoco

123 Acinetobacter baumannii is a Gram-negative bacterium tha

124 Acinetobacter baumannii is a Gram-negative coccobacillus

125 Acinetobacter baumannii is a Gram-negative opportunistic

126 Acinetobacter baumannii is a leading cause of multidrug-

127 Acinetobacter baumannii is a leading cause of ventilator

128 Acinetobacter baumannii is a multidrug-resistant (MDR) n

129 Acinetobacter baumannii is a nosocomial pathogen with a

130 Acinetobacter baumannii is a pathogen of increasing medi

131 Acinetobacter baumannii is a pathogen of major importanc

132 The multidrug resistant bacterium Acinetobacter baumannii is a significant cause of nosoco

133 Acinetobacter baumannii is a significant cause of opport

134 Acinetobacter baumannii is a significant source of nosoc

135 enem-associated outer membrane protein) from Acinetobacter baumannii is a small OM protein that has b

136 Multidrug-resistant Acinetobacter baumannii is among the most prevalent bact

137 Acinetobacter baumannii is an emerging bacterial pathoge

138 Acinetobacter baumannii is an emerging human pathogen an

139 Acinetobacter baumannii is an emerging nosocomial, oppor

140 Acinetobacter baumannii is an emerging opportunistic pat

141 Acinetobacter baumannii is an emerging, nosocomial patho

142 Acinetobacter baumannii is an important human pathogen d

143 Acinetobacter baumannii is an important nosocomial patho

144 Acinetobacter baumannii is an important nosocomial patho

145 Invasive disease due to Acinetobacter baumannii is an increasing problem in heal

146 Acinetobacter baumannii is an opportunistic human pathog

147 Acinetobacter baumannii is an opportunistic pathogen tha

148 Bacteremia caused by Acinetobacter baumannii is becoming more frequent among

149 Acinetobacter baumannii is challenging the healthcare co

150 Acinetobacter baumannii is emerging as an important noso

151 Acinetobacter baumannii is one of the most antibiotic-re

152 Extremely drug-resistant (XDR) Acinetobacter baumannii is one of the most commonly enco

153 Multidrug-resistant (MDR) Acinetobacter baumannii is one of the most difficult Gra

154 Acinetobacter baumannii is one of the most notorious hos

155 tivity relationship of vitroprocines against Acinetobacter baumannii is proposed.

156 Currently, Acinetobacter baumannii is recognized as one of the majo

157 CPNFs), including Pseudomonas aeruginosa and Acinetobacter baumannii, is necessary to prevent their d

158 se collection of epidemiologically unrelated Acinetobacter baumannii isolates to compare the robustne

159 Twenty-eight XDR Acinetobacter baumannii isolates were longitudinally rec

160 rbapenems (imipenem and meropenem); 90.8% of Acinetobacter baumannii isolates were susceptible to min

161 Sixteen isolates (4 Acinetobacter baumannii isolates, 6 Pseudomonas aerugino

162 or 99 isolates of Pseudomonas aeruginosa, 26 Acinetobacter baumannii isolates, and 11 Stenotrophomona

163 pplied to detect beta-lactamases in clinical Acinetobacter baumannii isolates.

164 Moraxella catarrhalis, and most recently in Acinetobacter baumannii, it has become increasingly appa

165 important Gram-negative pathogens including Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomo

166 stant clinical isolates of Escherichia coli, Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomo

167 am-negative bacteria, but colistin-resistant Acinetobacter baumannii lacking lipid A were isolated af

168 Extensively drug-resistant (XDR) Acinetobacter baumannii may cause serious infections in

169 coccus aureus (MRSA) and multidrug-resistant Acinetobacter baumannii (MDR-AB) were assessed.

170 ers for identifying carbapenem resistance in Acinetobacter baumannii, methicillin resistance in Staph

171 To successfully establish an infection, Acinetobacter baumannii must overcome the iron starvatio

172 -resistant Staphylococcus aureus (n=17), and Acinetobacter baumannii (n=15).

173 mophilus influenzae, Pseudomonas aeruginosa, Acinetobacter baumannii, Neisseria meningitidis, Bactero

174 c acid (A/C) for 100 consecutive isolates of Acinetobacter baumannii obtained from various clinical s

175 Infections with Acinetobacter baumannii, one of the most troublesome and

176 Found in Acinetobacter baumannii, OXA-24 is a class D carbapenem

177 rane protein A (OmpA) is a porin involved in Acinetobacter baumannii pathogenesis.

178 ment of a zebrafish infection model to study Acinetobacter baumannii pathogenesis.

179 Thirty-one Acinetobacter baumannii patients were matched to 62 cont

180 6, Pseudomonas aeruginosa, pandrug-resistant Acinetobacter baumannii (PDRAB), Staphylococcus aureus,

181 Acinetobacter baumannii persists in the medical environm

182 Infections by pan-drug resistant Acinetobacter baumannii plague military and civilian hea

183 Multidrug-resistant Acinetobacter baumannii presents a global medical crisis

184 The human pathogen Acinetobacter baumannii produces a siderophore called ac

185 in Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Ste

186 panresistant Gram-negative bacilli, such as Acinetobacter baumannii, requires consideration of nonan

187 oli, Vibrio cholerae, Bacillus subtilis, and Acinetobacter baumannii, respectively.

188 n of NAD metabolism in the emerging pathogen Acinetobacter baumannii revealed unique features suggest

189 Investigating the opportunistic pathogen Acinetobacter baumannii's response to Zn starvation, we

190 ork, we show that the opportunistic pathogen Acinetobacter baumannii senses and responds to blue ligh

191 The opportunistic human pathogen Acinetobacter baumannii strain M2 was found to produce d

192 ial released by treatment of cell walls from Acinetobacter baumannii strain O11 with hot, aqueous phe

193 e and rapid spreading of multidrug-resistant Acinetobacter baumannii strains has become a major healt

194 Multidrug-resistant Acinetobacter baumannii strains have increasingly result

195 (3) CFU mL(-1) of Pseudomonas aeruginosa and Acinetobacter baumannii strains that were undetectable u

196 faecalis, 1,356 Enterobacteriaceae, and 227 Acinetobacter baumannii strains were evaluated.

197 Acinetobacter baumannii strains were highly resistant to

198 t strains of some bacterial species, such as Acinetobacter baumannii strains, cannot be reliably iden

199 A strain of multidrug-resistant Acinetobacter baumannii that caused a 26% mortality rate

200 o MDR isolates of Pseudomonas aeruginosa and Acinetobacter baumannii through in vitro disk diffusion,

201 The ability of Acinetobacter baumannii to adhere to and persist on surf

202 a representative nosocomial human pathogen, Acinetobacter baumannii, to chlorhexidine to identify th

203 Acinetobacter baumannii was the predominant pathogen (37

204 comial pathogens, Pseudomonas aeruginosa and Acinetobacter baumannii, was also detected using this me

205 Using Acinetobacter baumannii, we provide initial insight into

206 es and blaOXA carbapenemases associated with Acinetobacter baumannii were noted.

207 a pneumoniae and platinum and silver against Acinetobacter baumannii were optimal.

208 l intensive care unit stay was prolonged for Acinetobacter baumannii when compared to controls (media

209 Acinetobacter baumannii, which causes serious infections

210 d carbacephalosporinase producing strains of Acinetobacter baumannii, which have been listed by the W

211 erobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii with various beta-lactamase susc

212 Extensively drug-resistant Acinetobacter baumannii (XDR-Ab) has emerged as a major